FMP
Royalty Pharma plc
RPRX
NASDAQ
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
32.47 USD
0.02 (0.0616%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
2.12B
2.29B
2.24B
2.35B
2.26B
2.3B
2.34B
2.39B
2.43B
2.47B
Revenue %
-
7.89
-2.28
5.24
-3.85
1.75
1.75
1.75
1.75
Ebitda
1.68B
1.45B
928.56M
1.89B
1.29B
1.48B
1.51B
1.53B
1.56B
1.59B
Ebitda %
79.34
63.5
41.51
80.15
57.07
64.31
64.31
64.31
64.31
Ebit
1.66B
1.43B
922.89M
1.49B
1.29B
1.39B
1.42B
1.44B
1.47B
1.49B
Ebit %
78.25
62.49
41.25
63.37
57.07
60.49
60.49
60.49
60.49
Depreciation
23.06M
23M
5.67M
395.13M
-
88.12M
89.66M
91.23M
92.83M
94.46M
Depreciation %
1.09
1
0.25
16.78
-
3.83
3.83
3.83
3.83
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
1.99B
2.8B
2.43B
495.31M
987.23M
1.65B
1.68B
1.71B
1.74B
1.77B
Total Cash %
93.87
122.44
108.52
21.04
43.61
71.7
71.7
71.7
71.7
Receivables
626.36M
682.66M
727.92M
775.09M
26.96M
580.44M
590.61M
600.95M
611.48M
622.2M
Receivables %
29.52
29.82
32.54
32.92
1.19
25.2
25.2
25.2
25.2
Inventories
657.14M
1
1
-
-
142.68M
145.18M
147.72M
150.31M
152.94M
Inventories %
30.97
0
0
-
-
6.19
6.19
6.19
6.19
Payable
10.78M
5.62M
7.91M
15.16M
13.37M
10.79M
10.98M
11.17M
11.36M
11.56M
Payable %
0.51
0.25
0.35
0.64
0.59
0.47
0.47
0.47
0.47
Cap Ex
-
-
-
-
-
-
-
-
-
-
Cap Ex %
-
-
-
-
-
-
-
-
-
Weighted Average Cost Of Capital
Price
32.47
Beta
Diluted Shares Outstanding
592.73M
Costof Debt
3.98
Tax Rate
After Tax Cost Of Debt
2.57
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
7.61B
Total Equity
19.25B
Total Capital
26.86B
Debt Weighting
28.34
Equity Weighting
71.66
Wacc
5
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
2.12B
2.29B
2.24B
2.35B
2.26B
2.3B
2.34B
2.39B
2.43B
2.47B
Ebitda
1.68B
1.45B
928.56M
1.89B
1.29B
1.48B
1.51B
1.53B
1.56B
1.59B
Ebit
1.66B
1.43B
922.89M
1.49B
1.29B
1.39B
1.42B
1.44B
1.47B
1.49B
Tax Rate
35.46
35.46
35.46
35.46
35.46
35.46
35.46
35.46
35.46
35.46
Ebiat
483.11M
551.85M
171.82M
996.03M
833.83M
606.34M
616.96M
627.77M
638.77M
649.96M
Depreciation
23.06M
23M
5.67M
395.13M
-
88.12M
89.66M
91.23M
92.83M
94.46M
Receivables
626.36M
682.66M
727.92M
775.09M
26.96M
580.44M
590.61M
600.95M
611.48M
622.2M
Inventories
657.14M
1
1
-
-
142.68M
145.18M
147.72M
150.31M
152.94M
Payable
10.78M
5.62M
7.91M
15.16M
13.37M
10.79M
10.98M
11.17M
11.36M
11.56M
Cap Ex
-
-
-
-
-
-
-
-
-
-
Ufcf
-766.55M
1.17B
134.52M
1.35B
1.58B
-4.28M
694.14M
706.31M
718.68M
731.27M
Wacc
5
5
5
5
5
Pv Ufcf
-4.08M
629.61M
610.13M
591.26M
572.97M
Sum Pv Ufcf
2.4B
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
5
Free Cash Flow T1
745.9M
Terminal Value
24.83B
Present Terminal Value
19.46B
Intrinsic Value
Enterprise Value
21.85B
Net Debt
6.68B
Equity Value
15.17B
Diluted Shares Outstanding
592.73M
Equity Value Per Share
25.6
Projected DCF
25.6 -0.268%
